Ocean Biomedical, Inc.

What they do

Ocean Biomedical is a Delaware-incorporated pharmaceutical preparations company listed on Nasdaq under the symbol OCEA, with warrants trading as OCEAW. It is a smaller reporting company and non-accelerated filer with principal executive offices at 55 Claverick St., Room 325, Providence, RI 02903, and reported 166,010,805 common shares outstanding as of March 31, 2025. The filings provided describe reporting, governance and financial matters rather than commercial-stage operations.

Revenue drivers

• No disclosed product or segment revenue — The source material discloses no product, licensing or collaboration revenue lines; the company is pre-revenue and funds operations from external capital.
• Equity and warrant-linked financing — Financing has come from issuance of common stock and warrants (OCEAW warrants exercisable at $11.50), which fund operations but dilute holders and carry exercise-price risk versus the $1.22 reference price on June 30, 2024.
• Nasdaq listing — Common stock and warrants trade on The Nasdaq Stock Market LLC, but repeated delisting notices since March 2025 put continued listing — and access to public capital markets — at risk.

Recent performance

The company has never reported revenue and has posted annual net losses in each of the last three fiscal years: $17.4M in 2022, $114.5M in 2023 and $9.5M in 2024. Diluted EPS was -$0.74, -$4.35 and -$0.34 for 2022, 2023 and 2024 respectively. Operating cash outflow was approximately $0.99M in 2022, $9.4M in 2023 and $4.2M in 2024. As of March 31, 2025, total assets were $1.6M, total liabilities were $94.0M, shareholder equity was negative $92.4M and cash was $0.8M.

Strategy

The 10-K/A filed April 29, 2025 was a limited amendment adding Part III governance and compensation disclosure and Section 302 certifications; it explicitly did not update other information for subsequent events. Management's disclosures in the 10-Q are framed by extensive forward-looking statement language and reference risk factors rather than a stated growth plan. No pipeline, clinical, partnership or commercial strategy details appear in the provided excerpts. Communications to the market since the last 10-K have been dominated by exchange listing matters, officer and director changes, and terminations of material agreements.

Risks

• Going-concern and liquidity risk — Cash of $0.8M against $94.0M of liabilities and $92.4M negative shareholder equity as of March 31, 2025 leaves minimal runway without new financing.
• Nasdaq delisting risk — The company disclosed delisting notices or listing-rule failures on March 20, April 23, July 23 and August 5, 2025, plus officer/director changes on April 23 and August 5.
• Contract termination risk — The company reported terminating material agreements on June 13 and July 16, 2025, which can disrupt research, manufacturing or partnering arrangements.
• No revenue and accumulated losses — Three consecutive years of net losses ($17.4M, $114.5M, $9.5M for 2022-2024) with no disclosed product revenue mean value depends on financing and future development outcomes.

Outlook

The filings provided contain no management guidance on revenue, product timelines or profitability. The 10-K/A states it does not update the original 10-K for subsequent events and the 10-Q is accompanied by broad forward-looking statement disclaimers. The 8-K record since April 2025 is dominated by listing-rule and organizational events rather than operating milestones.